Core Viewpoint - The company is committed to enhancing operational quality and efficiency while ensuring investor returns through its "Quality Improvement and Return Action Plan" for 2025, which aims to strengthen its market position and governance [1][10]. Group 1: Internal Strengthening and R&D - The company adheres to a "three trees" R&D philosophy, focusing on both breadth and depth in product development, with R&D expenses totaling 34.46 million yuan and a R&D expense ratio reflecting ongoing project progress [1][2]. - The company has launched innovative products in the GI, ESD&EMR, and ERCP fields, optimizing design and reducing clinical costs while enhancing product performance [2][3]. Group 2: Sales and Market Expansion - The company has expanded its sales network, covering over 2,540 hospitals, with a steady increase in the coverage of top-tier hospitals and the establishment of 450 effective cooperation channels [3][4]. - The company has successfully penetrated international markets, selling products in over 60 countries and adding 14 new overseas partners during the reporting period [4][5]. Group 3: Governance and Investor Relations - The company emphasizes investor returns, planning to distribute cash dividends amounting to 111.20 million yuan, which represents 37.90% of the net profit attributable to shareholders for 2024 [9][10]. - The company has established a robust governance structure in compliance with relevant laws and regulations, continuously improving internal controls and governance practices [10][11]. Group 4: Talent Development and Management - The company has built a high-quality R&D team with 187 personnel, a 47.24% increase year-on-year, focusing on multidisciplinary expertise to support product development and market expansion [7][8]. - The company has implemented a comprehensive human resource management system to optimize organizational structure and enhance cross-functional collaboration [7]. Group 5: Operational Efficiency and Cost Management - The company has improved manufacturing efficiency through process optimization and automation, leading to enhanced production capacity and cost management [8]. - The company maintains a stable gross profit margin, reinforcing its competitive advantage in the market [8].

截至发稿，安杰思市值为64亿元。 每经头条（nbdtoutiao）——时速21万公里，外星探测器伪装成彗星将"攻击"地球？哈佛知名教授：建 议全球建立"宇宙防御系统"！中国专家：并无明显异常 （记者 曾健辉） 每经AI快讯，安杰思（SH 688581，收盘价：79.19元）8月7日晚间发布公告称，公司第三届第三次董事 会会议于2025年8月6日在公司九楼会议室召开。会议审议了《关于公司2025年半年度报告全文及其摘要 的议案》等文件。 2024年1至12月份，安杰思的营业收入构成为：医疗器械占比99.41%，其他业务占比0.59%。 ...

Core Viewpoint - The report highlights the financial performance and growth potential of Hangzhou AGS MedTech Co., Ltd. in the minimally invasive endoscopic medical device sector, emphasizing the company's commitment to innovation and market expansion [1][3][10]. Financial Performance - The company achieved operating revenue of approximately 302.43 million yuan in the first half of 2025, representing a 14.56% increase compared to 264.00 million yuan in the same period last year [3][10]. - The total profit for the period was approximately 149.13 million yuan, a 2.78% increase from 145.10 million yuan year-on-year [3][10]. - The net profit attributable to shareholders was approximately 126.02 million yuan, reflecting a 1.26% increase from 124.45 million yuan in the previous year [3][10]. Industry Overview - The global medical device market is projected to grow from 542.21 billion USD in 2024 to 886.8 billion USD by 2032, with a compound annual growth rate (CAGR) of 6.3% [5]. - The Chinese medical device market has expanded from 370 billion yuan in 2016 to 1,032.8 billion yuan in 2023, with a CAGR of 16.12% [5][6]. - The endoscopic diagnosis and treatment market in China is expected to grow from approximately 15.6 billion yuan in 2023 to about 22 billion yuan by 2025 [6]. Business Model and Strategy - The company focuses on the research, development, production, and sales of minimally invasive endoscopic medical devices, with a product range that includes GI, EMR/ESD, and ERCP categories [7][8]. - The company employs a dual sales model, primarily using distribution for domestic sales and ODM for international markets [9][10]. - The company emphasizes a research and development strategy guided by clinical needs, aiming to innovate and optimize product performance [11][12]. Research and Development - The company has a robust R&D framework, with 40 new product development projects and 19 ongoing product design improvement projects [11][12]. - The R&D expenditure accounted for 11.39% of operating revenue, an increase from 9.79% in the previous year [3][10]. - The company has applied for a total of 421 patents, with 102 patents granted, enhancing its competitive edge in the market [13][14]. Market Expansion - The company has expanded its market presence, covering over 2,540 hospitals, with a steady increase in the coverage of top-tier hospitals [14][15]. - The company is actively exploring overseas markets, with products sold across six continents and a focus on establishing local operations in regions like Europe and North America [15][16]. - The company is investing in a production base in Thailand, which aims to enhance its manufacturing capabilities and overall competitiveness [15][16]. Corporate Governance and Quality Management - The company adheres to strict quality management standards, having obtained ISO 13485:2016 certification, ensuring compliance with international regulations [19][20]. - The company has implemented a comprehensive knowledge property management system to safeguard its innovations and competitive advantages [20][21]. - The company has received multiple government honors, reflecting its commitment to quality and operational excellence [16][21].

杭州安杰思医学科技股份有限公司2025 年半年度报告摘要 公司代码：688581 公司简称：安杰思 杭州安杰思医学科技股份有限公司 杭州安杰思医学科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本报告 "第三节 管理层讨论与分析"之"四、风险因素"。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 | | 公司股票简况 | | | | | --- | --- | --- | --- | --- | | 股票种类 股票上市交易所 | | 股票简称 | 股票代码 | 变更前股票简称 | | 上海证券交易所科 | | | | | | A股 | 安杰思 | 688581 | 不适用 | | | 创板 | | | | | | 公司存托凭证简况 | | | | | | □适用 √不适用 | | | | | | 联系人和联系方式 | | | | | | 联系人和联系方式 ...

Meeting Overview - The third meeting of the third supervisory board of Hangzhou Anjiasi Medical Technology Co., Ltd. was held on August 6, 2025, in a combination of on-site and remote formats, with all three supervisors present [1][2] - The meeting was chaired by the chairman of the supervisory board, Shi Baiming, and complied with the relevant provisions of the Company Law and the Articles of Association [1] Resolutions Passed - The supervisory board approved the proposal regarding the company's 2025 semi-annual report and its summary, affirming that the report complies with legal and regulatory requirements and accurately reflects the company's actual situation without any false statements or omissions [1][2] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming that the report objectively reflects the situation and that there were no violations in the use of raised funds during the reporting period [2][3]

Group 1 - The core viewpoint of the article is that Anjisi (688581.SH) reported a revenue of 302 million yuan for the first half of 2025, reflecting a year-on-year growth of 14.56% [1] - The net profit attributable to shareholders of the listed company reached 126 million yuan, showing a year-on-year increase of 1.26% [1] - The basic earnings per share (EPS) for the company is 1.5562 yuan [1]

Core Viewpoint - Anjiasi (688581.SH) reported a revenue of 302 million yuan for the first half of 2025, reflecting a year-on-year growth of 14.56% [1] - The net profit attributable to shareholders was 126 million yuan, showing a year-on-year increase of 1.26% [1] - The non-recurring net profit was 112 million yuan, which represents a year-on-year decline of 7.06% [1] - Basic earnings per share stood at 1.5562 yuan [1] Financial Performance - Revenue for the reporting period reached 302 million yuan, marking a 14.56% increase compared to the previous year [1] - Net profit attributable to shareholders was 126 million yuan, with a slight increase of 1.26% year-on-year [1] - Non-recurring net profit decreased to 112 million yuan, reflecting a decline of 7.06% year-on-year [1] - Basic earnings per share were reported at 1.5562 yuan [1] Cash Flow Analysis - The change in net cash flow from operating activities was primarily due to a decrease in interest income and an increase in the number of R&D personnel, along with higher employee compensation [1]

代码：688581 证券简称：安杰思 公告编号：2025-046 杭州安杰思医学科技股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》和《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科 创板股票上市规则》等有关规定，杭州安杰思医学科技股份有限公司（以下简称 "公司""安杰思"或"本公司"）编制了《2025 年半年度募集资金存放与实 际使用情况的专项报告》。具体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2023〕481号），同意公司首次公 开发行股票的注册申请。并经上海证券交易所同意，公司首次向社会公开发行人 民币普通股（A股）股票1,447.00万股，本次发行价格为每股人民币125.80元，募 集资金总额为人民币182,032.60 ...

杭州安杰思医学科技股份有限公司 关于公司 2025 年度提质增效重回报专项行动方案的半年度评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，践行"以投资者为本" 的上市公司发展理念，推动杭州安杰思医学科技股份有限公司（以下简称"公司"） 持续优化经营、规范治理和积极回报投资者，大力提高公司质量，助力信心提振、 资本市场稳定和经济高质量发展，基于对公司未来发展前景的信心、对公司价值 的认可和切实履行社会责任,公司于 2025 年 4 月 21 日发布了《2025 年度"提质增 效重回报"专项行动方案》，通过持续加强自身价值创造能力，切实履行上市公司 的责任和义务，回报投资者信任，维护公司在资本市场形象，共同促进资本市场 平稳健康发展。现将行动方案进展半年度评估情况报告如下： 一、夯实企业内部实力，助力企业优质发展 1、坚持自主创新，持续强化研发核心竞争力 公司始终坚持"三棵树"的研发理念，密切关注行业发展的最新动态并结合 不断积累的技术创新经验，集中资源开发一系列新产品，在保持产品研发方向广 度的同时追求产品研发深度，持续强化公司研发的核心竞争力，进而构建公司产 品研发的护城河。报告期内，公司研发费用共计 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-048 杭州安杰思医学科技股份有限公司 第三届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 杭州安杰思医学科技股份有限公司（以下简称"公司"）第三届监事会第三次会 议于 2025 年 8 月 6 日以现场结合通讯的方式在公司九楼会议室召开。本次会议通知 已于 2025 年 7 月 25 日以专人送达方式向全体监事发出，本次会议由监事会主席时百 明主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集和召开程序符合 《公司法》和《公司章程》的有关规定。 会议由监事会主席时百明主持召开，全体与会监事经认真审议和表决，形成以下 决议： 二、监事会会议审议情况 （一）审议通过了《关于公司 2025 年半年度报告全文及其摘要的议案》 监事会认为：公司《2025 年半年度报告全文》及其摘要的编制符合法律、法规、 中国证监会和上海证券交易所的相关规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记 ...